Immunome Inc. (IMNM) stock
IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.78−0.40 (-2.33%)
Close on Nov 18, 2026Market cap $1.91BP/E –Yield –
Immunome net income
Net income is the profit left for shareholders after every expense, interest and tax.
Immunome's net income for the twelve months ending Mar 31, 2026 was -$224.59M. For fiscal 2025 it was -$212.39M. The highest annual figure on record is -$10.44M in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$212.39M | – |
| FY2024 | Dec 31, 2024 | -$292.96M | – |
| FY2023 | Dec 31, 2023 | -$106.81M | – |
| FY2022 | Dec 31, 2022 | -$36.90M | – |
| FY2021 | Dec 31, 2021 | -$24.71M | – |
| FY2020 | Dec 31, 2020 | -$17.84M | – |
| FY2019 | Dec 31, 2019 | -$10.44M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$53.84M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$57.46M | – |
| Q2 FY2025 | Jun 30, 2025 | -$43.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.64M | – |
| Q4 FY2024 | Dec 31, 2024 | -$80.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$47.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$36.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$129.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$92.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.24M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.68M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.74M | – |
See a number that looks wrong?